DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Receives Average Rating of “Moderate Buy” from Brokerages

DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) has been given a consensus recommendation of “Moderate Buy” by the five research firms that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation and four have given a buy recommendation to the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $12.00.

A number of analysts have commented on DMAC shares. HC Wainwright restated a “buy” rating and set a $12.00 price target on shares of DiaMedica Therapeutics in a research report on Tuesday, August 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of DiaMedica Therapeutics in a research note on Friday, July 17th. Finally, Wall Street Zen raised DiaMedica Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, June 6th.

Hedge Funds Weigh In On DiaMedica Therapeutics

Several hedge funds have recently modified their holdings of the company. AXQ Capital LP bought a new stake in shares of DiaMedica Therapeutics in the 4th quarter worth $96,000. AWM Investment Company Inc. bought a new position in DiaMedica Therapeutics during the second quarter valued at about $253,000. Bank of America Corp DE grew its holdings in DiaMedica Therapeutics by 62.5% during the first quarter. Bank of America Corp DE now owns 42,768 shares of the company’s stock worth $290,000 after acquiring an additional 16,446 shares during the period. World Investment Advisors grew its holdings in DiaMedica Therapeutics by 7.7% during the fourth quarter. World Investment Advisors now owns 36,975 shares of the company’s stock worth $294,000 after acquiring an additional 2,650 shares during the period. Finally, Renaissance Technologies LLC bought a new stake in DiaMedica Therapeutics in the first quarter worth about $356,000. 10.12% of the stock is currently owned by institutional investors and hedge funds.

DiaMedica Therapeutics Stock Performance

Shares of DMAC opened at $7.94 on Friday. DiaMedica Therapeutics has a one year low of $5.24 and a one year high of $10.42. The stock’s fifty day moving average is $6.76 and its 200-day moving average is $6.61. The firm has a market capitalization of $428.17 million, a price-to-earnings ratio of -11.03 and a beta of 0.98.

DiaMedica Therapeutics (NASDAQ:DMAC) last posted its quarterly earnings data on Monday, August 10th. The company reported ($0.19) earnings per share for the quarter, topping the consensus estimate of ($0.20) by $0.01. Analysts forecast that DiaMedica Therapeutics will post -0.84 EPS for the current fiscal year.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for serious diseases with limited therapeutic options. The company’s research is centered on therapies intended to address neurological and kidney-related conditions.

DiaMedica’s lead product candidate is rinvecalin, also known as DM199, a recombinant form of human tissue kallikrein-1. The company is evaluating rinvecalin as a potential treatment for acute ischemic stroke and kidney diseases, including conditions involving impaired renal function.